Navigation Links
Repligen Reports Third Quarter Fiscal Year 2009 Financial Results
Date:2/5/2009

ta: 2008 2008 ---------- -------- Cash, cash equivalents and marketable securities* $64,509,469 $60,589,054 Working capital 49,774,132 49,831,376 Total assets 75,276,660 68,839,707 Long-term obligations 86,958 143,043 Accumulated deficit (111,164,023) (120,576,820) Stockholders' equity 71,434,506 64,106,854 *does not include restricted cash

This press release contains forward-looking statements which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The forward-looking statements in this release do not constitute guarantees of future performance. Investors are cautioned that statements in this press release which are not strictly historical statements, including, without limitation, statements regarding current or future financial performance and position, management's strategy, plans and objectives for future operations, plans and objectives for product development, plans and objectives for present and future clinical trials and results of such trials, plans and objectives for regulatory approval, litigation, intellectual property, product development, manufacturing plans and performance such as the anticipated growth in the monoclonal antibody market and our other target markets and projected growth in product sales, constitute forward-looking statements. Such forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated, including, without limitation, risks associated with: the success of current and future collaborative relationships, the market acceptance of our products, our ability to compete with larger, better financed pharmaceutical and biotechnology c
'/>"/>

SOURCE Repligen Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Repligen to Present at the BIO CEO & Investor Conference Monday, February 9th, 11:30 a.m. EST
2. Repligen Announces Conference Call of Third Quarter Fiscal Year 2009 Results
3. Repligen to Present at the Rodman & Renshaw 10th Annual Healthcare Conference Monday, November 10th, 4:55 p.m. EST
4. Repligen to Present at the 2008 UBS Global Life Sciences Conference Wednesday, September 24th, 1:00 p.m. EDT
5. Repligen Announces Publication of Positive Results with Proprietary HDAC Inhibitor in Huntingtons Disease Model
6. Repligen Receives Research Grants to Support Friedreichs Ataxia Development Program
7. Repligen Announces Conference Call of First Quarter Fiscal Year 2009 Results
8. Repligen Reports Fourth Quarter and Fiscal Year 2008 Financial Results
9. Repligen Announces Settlement with Bristol-Myers Squibb in Orencia(R) Lawsuit
10. Repligen Announces Conference Call of Third Quarter Fiscal Year 2008 Results
11. Sangamo BioSciences Reports Fourth Quarter and Full Year 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... August 28, 2014 PrimeSource Building ... materials, selected SoundConnect to support their ... based audio and web conferencing platform GlobalMeet powered ... PrimeSource’s employees’ needs. SoundConnect delivers award winning ... PrimeSource Building Products will be utilizing GlobalMeet ...
(Date:8/27/2014)... Varian Medical Systems today broke ground ... Lake City manufacturing facility and allow for the consolidation ... create 1,000 new full time jobs in the state ... home to hardworking people with immense engineering and technical ... success in the manufacturing of our state-of-the-art X-ray technology,” ...
(Date:8/27/2014)... Livermore, California (PRWEB) August 27, 2014 ... (LLNL), through Lawrence Livermore National Security ... million to develop and deliver a state-of-the-art laser ... Beamlines facility (ELI Beamlines), under construction in the ... design performance, the laser system, called the " ...
(Date:8/27/2014)... mysteries is how plants survive impact by the ... rays, while using this energy for photosynthesis. The ... plant,s blades quickly dissipate the energy throughout the ... at DTU Physics have now managed to successfully ... bacteria contain light-absorbing proteins which play a role ...
Breaking Biology Technology:PrimeSource Chooses SoundConnect as Collaboration Provider 2Varian Medical Systems Groundbreaking on Facility Expansion Triggers Influx of New Jobs to Salt Lake 2Varian Medical Systems Groundbreaking on Facility Expansion Triggers Influx of New Jobs to Salt Lake 3LLNL Synchs up with ELI Beamlines on Timing System 2LLNL Synchs up with ELI Beamlines on Timing System 3DTU researchers film protein quake for the first time 2
... MISSISSAUGA, ON, Dec. 14 /PRNewswire-FirstCall/ - YM BioSciences Inc. ... life sciences product development company that identifies and advances ... stages of development, today announced that it has priced ... a price to the public of $1.60 per share. ...
... CAMBRIDGE, Mass., Dec. 14, 2010 Tolerx, Inc., a ... and cancer by modulating T cell activity, today announced ... to assess the safety, tolerability, pharmacokinetic, and pharmacodynamic profiles ... immune system by enabling T cells to more effectively ...
... Cambridge, Mass., December 6, 2010 Utilizing a century-old ... at Harvard University have demonstrated, for the first time, ... collaboration with researchers from Hamamatsu Photonics in Hamamatsu City, ... University of Magdeburg, Germany, the advance has a wide ...
Cached Biology Technology:YM BIOSCIENCES PRICES $40 MILLION PUBLIC OFFERING 2YM BIOSCIENCES PRICES $40 MILLION PUBLIC OFFERING 3Tolerx Initiates Phase 1 Clinical Trial of TRX518, a First-in-Class anti-GITR Antibody for the Treatment of Cancer 2Tolerx Initiates Phase 1 Clinical Trial of TRX518, a First-in-Class anti-GITR Antibody for the Treatment of Cancer 3Capasso lab demonstrates highly unidirectional 'whispering gallery' microlasers 2
(Date:8/28/2014)... to Research Careers) Program has announced the travel award ... October 18 22, 2014 in San Diego, California. ... of students, post doctorates and scientists from underrepresented groups ... to encourage the participation of young scientists at the ... conferred 16 awards totaling $29,600., The FASEB MARC Program ...
(Date:8/28/2014)... Researchers at the University of Minnesota have developed ... to be used for muscle regeneration research as well ... FSHD. , The research is published in the current ... There is no treatment for FSHD, which is thought ... muscular dystrophy. FSHD is an unusual genetic disorder because, ...
(Date:8/28/2014)... support of peer groups and clinicians is critical ... to recent University of Georgia research. , A ... County area determined that role models for successful ... of infants. , "Mothers who received that support ... said study co-author Alex Anderson, an associate professor ...
Breaking Biology News(10 mins):UMN researchers find animal model for understudied type of muscular dystrophy 2Breastfeeding study shows need for effective peer counseling programs 2
... low intake of folate and vitamin B12 increases the ... among nearly 3,000 middle-aged and elderly Finnish subjects. On ... an increased risk for the metabolic syndrome. Based on ... separate depressive subtypes with different etiologies in terms of ...
... This press release is available in Spanish . ... of amino acids and they play a fundamental role in ... in genes; they, therefore, carry out numerous functions in an ... material), bioregulating (they form part of enzymes) and a long ...
... how life began on a molecular level has been a ... on a possible mechanism by which life may have gotten ... early Earth. Researchers have proposed several competing theories for ... before the first genes or living cells came to be. ...
Cached Biology News:Lack of nutrients and metabolic syndrome linked to different subtypes of depression 2Using computational biology for the annotation of proteins 2Using computational biology for the annotation of proteins 3Model sheds light on the chemistry that sparked the origin of life 2
... Tissue Staining Kits are intended for localization ... histological and cytological specimens. These kits may ... by either R&D Systems or by other ... formation of the Avidin-Biotin Complex (ABC) with ...
... Designed specifically for high efficiency ... Low toxicity reagent proven to ... range of cell types. Results ... 95% of target gene expression. ...
... Purification Protocols covers a wide range of ... and experienced researchers in all areas of ... from the books preface illustrates just how ... research library., The chapters introduce the theoretical ...
... jetSI-ENDO is an easy-to-use siRNA transfection reagent ... endogenous genes in a variety of cell ... with an optimized, straightforward protocol. High levels ... obtained following transfection of 20 to 100 ...
Biology Products: